Papers/PMID:36159792
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Frontiers in immunology2022The record
4 findings · 1 compound · 4 endpoints
What it reported
How to read these marksWhat moved
4 findings
- ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3
“The results showed that curcumin reduced HOMA-IR compared with placebo [WMD = -0.28, 95% CI (-0.36, -0.20), P < 0.00001].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 343
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.28 mean difference, 95% CI -0.36 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
curcumin — decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×7“The results showed that curcumin reduced BMI compared with placebo [weighted mean difference (WMD) = -0.49, 95% CI (-0.81, -0.18), P = 0.002].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 462
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.49 mean difference, 95% CI -0.81 to -0.18
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
curcumin — decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The results showed that curcumin reduced ALT compared with placebo [SMD = -0.55, 95% CI (-1.01, -0.09), P = 0.02].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 639
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.55 standardised mean difference, 95% CI -1.01 to -0.09
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
curcumin — decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The results showed that curcumin reduced AST compared with placebo [SMD = -0.48, 95% CI (-0.76, -0.20), P = 0.0007].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 681
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.48 standardised mean difference, 95% CI -0.76 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink